Study of 600 TB patients in Mumbai found 51% with pre-XDR-TB and 15.5% with MDR-TB. Whole genome sequencing crucial for accurate treatment decisions.

New research from Trinity team at St James's Hospital improves our understanding of how tuberculosis infection causes lung damage and how we might prevent this.

University of Oxford researchers have for the first time established a controlled human infection model for tuberculosis (TB) that infects people via the lungs – the way TB enters the body.

The International Union Against Tuberculosis and Lung Disease released the April 2024 issue of IJTLD OPEN – a fully-compliant, open access journal to enhance the coverage of TB and lung disease.

The International Journal of Tuberculosis and Lung Disease (IJTLD) is the official publication of the International Union Against Tuberculosis and Lung Disease (The Union).

New research being presented at this year's ESCMID Global Congress (formerly ECCMID) in Barcelona, Spain (27–30 April) has found compelling evidence that tuberculosis (TB) can have a lasting impact on the lungs of individuals who have been successfully treated for the disease.

The WHO BPaLM Accelerator Platform was established in January 2023, right after the update of the World Health Organization (WHO) guidelines on the treatment of drug-resistant TB in 2022. The purpose of the WHO BPaLM Accelerator Platform is to support countries and stakeholders in information exchange and technical discussions to address challenges in the adoption and implementation of the BPaLM/BPaL regimen (consisting of bedaquiline, pretomanid, linezolid and moxifloxacin, with the provision of dropping moxifloxacin in case of confirmed resistance to fluoroquinolones). This is also to support the Call to Action on rolling out of the BPaLM regimen and other short regimens for treatment of drug-resistant TB that was initiated by WHO and its multiple partners. 

The World Health Organization (WHO) Global Tuberculosis Programme is launching a call for expressions of interest, seeking collaborators to design and conduct a series of youth engagement campaigns in selected countries on ending TB.

A webinar, organized by the Global Vaccine and Immunization Research Forum (GVIRF), brought together experts to discuss the status of TB vaccine development across the value chain, from articulation of the public health and economic need for new TB vaccines through the status and strategies for product development, to the considerations for approval, policy recommendation and use.